Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arena Pharmaceuticals, Inc. (NASDAQ: ARNA).

Full DD Report for ARNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARNA)

Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17
Your Daily Pharma Scoop: Arena Positive, Omeros's New Designation, Zai Lab's Phase 3 Dosing Begins
Stocks in News: Arena Pharm's long-acting ralinepag shows encouraging action in early-stage studies; shares up 2% Discussion: Arena Pharmaceuticals ( ARNA ) presented the data from two Phase 1 clinical trials evaluating the pharmacokinetics of its extended-release formulatio...
Source: SeekingAlpha
Date: August, 29 2018 21:22
Arena Pharm's long-acting ralinepag shows encouraging action in early-stage studies; shares up 2%
Arena Pharmaceuticals ( ARNA +1.9% ) is up on average volume on the heels of its announcement of data from two Phase 1 clinical trials evaluating the pharmacokinetics of its extended-release formulation of ralinepag, a prostacyclin receptor agonist in development for the treatment of pul...
Source: SeekingAlpha
Date: August, 28 2018 15:23
Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and ...
Source: PR Newswire
Date: August, 28 2018 13:54
Genkyotex advancing PBC candidate GKT831, Phase 2 data readout in coming months
French biotech Genkyotex announces the completion of enrollment 90 subjects necessary for an interim analysis in its Phase 2 clinical trial evaluating lead candidate GKT831 in patients with primary biliary cholangitis (PBC). Preliminary results, expected this fall, will be assessed when pa...
Source: SeekingAlpha
Date: August, 27 2018 13:01
Is The Bottom In For Celgene?
Celgene Corporation ( CELG ) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biop...
Source: SeekingAlpha
Date: August, 14 2018 09:00
New Research Coverage Highlights Arena Pharmaceuticals, Varian Medical, SS&C Technologies, Globus Medical, Zynga, and Diamondrock Hospitality - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Varian Medical Systems, Inc. (...
Source: GlobeNewswire
Date: August, 14 2018 08:25
Liquidia: Is It Worth Getting On Board Early?
Liquidia Technologies ( LQDA ) is a very interesting IPO story in 2018. The pharmaceutical upstart recently completed its IPO, with the stock going public at $11 per share. Over the past couple of weeks, shares have risen some 20% to $13 and change. Playing a stock on IPO can be a dangerous ga...
Source: SeekingAlpha
Date: August, 13 2018 22:26
United Therapeutics Releases Positive Data On PAH Drug - What Investors Should Know.
United Therapeutics ( UTHR ) announced today that the company has very positive data on a clinical trial related to Orenitram Extended Release tablets indicated for the treatment of pulmonary arterial hypertension ((PAH)). United is one of the market leaders in the treatment of this disease,...
Source: SeekingAlpha
Date: August, 08 2018 22:55
Arena Reports Loss As Expected - Pipeline Will Drive The Stock
The second quarter of 2018 seems like a "pause quarter" in the Arena Pharmaceutical (ARNA) story. Essentially, the company seems to be well-positioned with a robust pipeline but will not have any "sexy" news to report for the next couple of quarters, absent a partnership or M&A activity. ...
Source: SeekingAlpha
Date: August, 07 2018 23:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1241.5042.634143.6841.38363,132
2018-12-1141.6540.8441.9340.36191,370
2018-12-1040.3840.9041.73538.82265,333
2018-12-0739.9540.43541.2939.95396,452
2018-12-0639.5140.1840.7539.0601297,001

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1274,079145,38650.9533Short
2018-12-1126,78549,19454.4477Short
2018-12-1061,46683,55673.5626Short
2018-12-0760,793230,13526.4162Cover
2018-12-0637,22982,01245.3946Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARNA.


About Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

Logo for Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

Not available

 

Contact Information

 

 

Current Management

  • Jack Leif / President, CEO

Current Share Structure

  • Market Cap: $1,797,509,340 - 05/14/2018
  • Issue and Outstanding: 39,401,783 - 03/09/2018

 


Recent Filings from (NASDAQ: ARNA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018

 

 


Daily Technical Chart for (NASDAQ: ARNA)

Daily Technical Chart for (NASDAQ: ARNA)


Stay tuned for daily updates and more on (NASDAQ: ARNA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARNA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ARNA and does not buy, sell, or trade any shares of ARNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/